These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31116261)

  • 1. Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial.
    Kavanagh BE; Williams LJ; Berk M; Turner A; Jackson HJ; Mohebbi M; Kanchanatawan B; Ashton MM; Ng CH; Maes M; Berk L; Malhi GS; Dowling N; Singh AB; Dean OM
    Braz J Psychiatry; 2020; 42(1):14-21. PubMed ID: 31116261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.
    Dean OM; Kanchanatawan B; Ashton M; Mohebbi M; Ng CH; Maes M; Berk L; Sughondhabirom A; Tangwongchai S; Singh AB; McKenzie H; Smith DJ; Malhi GS; Dowling N; Berk M
    Aust N Z J Psychiatry; 2017 Aug; 51(8):829-840. PubMed ID: 28578592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K; Andersen HF; Reines EH
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder.
    Mohebbi M; Dodd S; Dean OM; Berk M
    Eur Psychiatry; 2018 Sep; 53():17-22. PubMed ID: 29859377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial.
    Husain MI; Chaudhry IB; Husain N; Khoso AB; Rahman RR; Hamirani MM; Hodsoll J; Qurashi I; Deakin JF; Young AH
    J Psychopharmacol; 2017 Sep; 31(9):1166-1175. PubMed ID: 28857658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting.
    Ishak WW; Balayan K; Bresee C; Greenberg JM; Fakhry H; Christensen S; Rapaport MH
    Qual Life Res; 2013 Apr; 22(3):585-96. PubMed ID: 22544416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social functioning: should it become an endpoint in trials of antidepressants?
    Bech P
    CNS Drugs; 2005; 19(4):313-24. PubMed ID: 15813645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
    Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
    J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials.
    Zazula R; Husain MI; Mohebbi M; Walker AJ; Chaudhry IB; Khoso AB; Ashton MM; Agustini B; Husain N; Deakin J; Young AH; Berk M; Kanchanatawan B; Ng CH; Maes M; Berk L; Singh AB; Malhi GS; Dean OM
    Aust N Z J Psychiatry; 2021 Aug; 55(8):784-798. PubMed ID: 33092404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.
    Berk M; Turner A; Malhi GS; Ng CH; Cotton SM; Dodd S; Samuni Y; Tanious M; McAulay C; Dowling N; Sarris J; Owen L; Waterdrinker A; Smith D; Dean OM
    BMC Med; 2019 Jan; 17(1):18. PubMed ID: 30678686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
    Endicott J; Lam RW; Hsu MA; Fayyad R; Boucher M; Guico-Pabia CJ
    J Affect Disord; 2014 Sep; 166():307-14. PubMed ID: 25012446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
    Blum SI; Tourkodimitris S; Ruth A
    J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.